Literature DB >> 26045738

Protective effects of isorhamnetin on apoptosis and inflammation in TNF-α-induced HUVECs injury.

Tie-Long Chen1, Guang-Li Zhu1, Jian-An Wang2, Guo-Dong Zhang1, Hong-Fei Liu1, Jin-Ru Chen1, Yu Wang3, Xiao-Long He1.   

Abstract

Little is known about the role of isorhamnetin on endothelial cell apoptosis and inflammation when insulted by TNF-α injury. In our study, HUVECs were treated with TNF-α for 6 hours. HUVECs apoptosis were detected using flow cytometry. The expressions of ICAM-1, VCAM-1, E-selectin, NF-κB, AP-1 and eNOS were determined with western blotting or flow cytometry. The results showed TNF-α increased of apoptosis and the expression of ICAM-1, VCAM-1 and E-selectin in HUVECs, accompanied by significant augmentation of NF-κB and AP-1 expression. Pretreatment with isorhamnetin significantly reduced apoptosis in TNF-α-treated HUVECs. Moreover, isorhamnetin significantly attenuated TNF-α-induced upregulation of ICAM-1, VCAM-1, AP-1, E-selectin and NF-κB expression. Meanwhile, isorhamnetin also increased the expression of eNOS. So, isorhamnetin could suppress TNF-α-induced apoptosis and inflammation by blocking NF-κB and AP-1 signaling in HUVECs, which might be one of the underlying mechanisms for treatment of coronary heart disease.

Entities:  

Keywords:  AP-1; E-selectin; HUVECs; ICAM-1; Isorhamnetin; NF-κB; VCAM-1; apoptosis; eNOS

Mesh:

Substances:

Year:  2015        PMID: 26045738      PMCID: PMC4440047     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

Review 1.  Cellular adhesion and the endothelium: E-selectin, L-selectin, and pan-selectin inhibitors.

Authors:  Marilyn J Telen
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-17       Impact factor: 3.722

2.  Hypoxia-induced apoptosis in endothelial cells and embryonic stem cells.

Authors:  C -N Lee; W -F Cheng; M -C Chang; Y -N Su; C -A Chen; F -J Hsieh
Journal:  Apoptosis       Date:  2005-08       Impact factor: 4.677

3.  Isorhamnetin prevent endothelial cell injuries from oxidized LDL via activation of p38MAPK.

Authors:  Meihua Bao; Yijia Lou
Journal:  Eur J Pharmacol       Date:  2006-07-22       Impact factor: 4.432

Review 4.  Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.

Authors:  G Chinetti; J C Fruchart; B Staels
Journal:  Inflamm Res       Date:  2000-10       Impact factor: 4.575

5.  TNF-alpha alters nitric oxide- and endothelium-derived hyperpolarizing factor-mediated vasodilatation in human omental arteries.

Authors:  J C Gillham; J E Myers; P N Baker; M J Taggart
Journal:  Hypertens Pregnancy       Date:  2008       Impact factor: 2.108

Review 6.  Nuclear factor kappa B--molecular biomedicine: the next generation.

Authors:  Peter Celec
Journal:  Biomed Pharmacother       Date:  2004 Jul-Aug       Impact factor: 6.529

7.  The protective role of NF-kappaB and AP-1 in arsenite-induced apoptosis in aortic endothelial cells.

Authors:  Tsui-Chun Tsou; Feng-Yuan Tsai; Meng Chan Wu; Louis W Chang
Journal:  Toxicol Appl Pharmacol       Date:  2003-09-01       Impact factor: 4.219

8.  NF-kappaB, but not p38 MAP kinase, is required for TNF-alpha-induced expression of cell adhesion molecules in endothelial cells.

Authors:  Suja Rajan; Jianming Ye; Shanshan Bai; Faqing Huang; Yan-Lin Guo
Journal:  J Cell Biochem       Date:  2008-10-01       Impact factor: 4.429

9.  Plant flavonol isorhamnetin attenuates chemically induced inflammatory bowel disease via a PXR-dependent pathway.

Authors:  Wei Dou; Jingjing Zhang; Hao Li; Sandhya Kortagere; Katherine Sun; Lili Ding; Gaiyan Ren; Zhengtao Wang; Sridhar Mani
Journal:  J Nutr Biochem       Date:  2014-05-09       Impact factor: 6.048

10.  Effects of four medicinal herbs on human vascular endothelial cells in culture.

Authors:  Shanhong Ling; Lina Nheu; Aozhi Dai; Zhixin Guo; Paul Komesaroff
Journal:  Int J Cardiol       Date:  2007-08-13       Impact factor: 4.164

View more
  6 in total

1.  Evidence and Characteristics of Traditional Chinese Medicine for Coronary Heart Disease Patients With Anxiety or Depression: A Meta-Analysis and Systematic Review.

Authors:  Baofu Wang; Yu Teng; Yang Li; Sijia Lai; Yang Wu; Shiqi Chen; Tong Li; Xiaowan Han; Hufang Zhou; Yu Wang; Ziwen Lu; Haiyan Li; Yukun Ding; Liang Ma; Mingjing Zhao; Xian Wang
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

2.  Involvement of the NF-κB signaling pathway in the renoprotective effects of isorhamnetin in a type 2 diabetic rat model.

Authors:  Shujuan Qiu; Guiling Sun; Yunxia Zhang; Xiangling Li; Rong Wang
Journal:  Biomed Rep       Date:  2016-03-22

3.  Phytochemical Analysis by HPLC-HRESI-MS and Anti-Inflammatory Activity of Tabernaemontana catharinensis.

Authors:  José Ivan Marques; Jovelina Samara Ferreira Alves; Manoela Torres-Rêgo; Allanny Alves Furtado; Emerson Michell da Silva Siqueira; Eder Galinari; Daline Fernandes de Souza Araújo; Gerlane Coelho Bernardo Guerra; Eduardo Pereira de Azevedo; Matheus de Freitas Fernandes-Pedrosa; Silvana Maria Zucolotto
Journal:  Int J Mol Sci       Date:  2018-02-24       Impact factor: 5.923

4.  Macrophages enhance lipopolysaccharide induced apoptosis via Ang1 and NF-κB pathways in human umbilical vein endothelial cells.

Authors:  Guo-Long Cai; Zhou-Xin Yang; Dong-Yang Guo; Cai-Bao Hu; Mo-Lei Yan; Jing Yan
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.379

Review 5.  Proteomic Analysis of Anticancer TCMs Targeted at Mitochondria.

Authors:  Yang Wang; Ru-Yuan Yu; Qing-Yu He
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-19       Impact factor: 2.629

6.  Isorhamnetin alleviates lipopolysaccharide-induced inflammatory responses in BV2 microglia by inactivating NF-κB, blocking the TLR4 pathway and reducing ROS generation.

Authors:  Shin Young Kim; Cheng-Yun Jin; Cheol Hong Kim; Young Hyun Yoo; Sung Hyun Choi; Gi-Young Kim; Hyun Min Yoon; Hwan Tae Park; Yung Hyun Choi
Journal:  Int J Mol Med       Date:  2018-11-20       Impact factor: 4.101

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.